UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000003159
Receipt number R000003833
Scientific Title Autologous peripheral blood stem cell transplantation using MEAM regimen with HAART for refractory and relapsed HIV associated lymphoma: multicentered phase2 clinical trial
Date of disclosure of the study information 2010/02/10
Last modified on 2016/06/16 07:21:19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Autologous peripheral blood stem cell transplantation using MEAM regimen with HAART for refractory and relapsed HIV associated lymphoma: multicentered phase2 clinical trial

Acronym

Auto PBSCT for refractory and relapsed HIV associated lymphoma (ARL209)

Scientific Title

Autologous peripheral blood stem cell transplantation using MEAM regimen with HAART for refractory and relapsed HIV associated lymphoma: multicentered phase2 clinical trial

Scientific Title:Acronym

Auto PBSCT for refractory and relapsed HIV associated lymphoma (ARL209)

Region

Japan


Condition

Condition

Refractory and relapsed HIV associated lymphoma

Classification by specialty

Hematology and clinical oncology Infectious disease

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the safety and efficacy of autologous stem cell transplantation for refractory and relapsed HIV associated lymphoma.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

Engraftment and survival at day 100 post transplantation

Key secondary outcomes

1year and 2year overall survival
progression free survival
event free survival
therapy related toxicity
remission rate
number of CD4 positive cell and quantity of HIV-RNA


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine Maneuver

Interventions/Control_1

autologous stem cell transplantation using MEAM regimen

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >=

Gender

Male and Female

Key inclusion criteria

HIV positive
refractory to first line chemotherapy and relapsed HIV associated lymphoma

Key exclusion criteria

heart failure, live dysfunction, renal dysfunction
uncontrollable opportunistic infection
uncontrollable diabetes
uncontrollable HIV infection by HAART

Target sample size

18


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shotaro Hagiwara

Organization

National Center for Global Health and Medicine

Division name

Division of Hematology

Zip code


Address

1-21-1Toyama, Shinjuku, Tokyo

TEL

81-3-3202-7181

Email

shagiwar@hosp.ncgm.go.jp


Public contact

Name of contact person

1st name
Middle name
Last name Shotaro Hagiwara

Organization

National Center for Global Health and Medicine

Division name

Division of Hematology

Zip code


Address

1-21-1Toyama, Shinjuku, Tokyo, JAPAN

TEL

+81-3-3202-7181

Homepage URL


Email

shagiwar@hosp.ncgm.go.jp


Sponsor or person

Institute

Research fund of Ministry Health, Labour and Welfare for a counter measure against AIDS, Okada group and Tanabe group

Institute

Department

Personal name



Funding Source

Organization

Ministry of Health, Labour and Welfare

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2010 Year 02 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2010 Year 02 Month 01 Day

Date of IRB


Anticipated trial start date

2010 Year 02 Month 01 Day

Last follow-up date

2018 Year 03 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 02 Month 09 Day

Last modified on

2016 Year 06 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003833


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name